Clinical trials
Lymphoproliferative Disease clinical trials
Below are recruiting lymphoproliferative disease clinical trials, each written for real people, not researchers. We’re tracking 21 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03394365RecruitingPhase 3
Tabelecleucel for EBV-related lymphoma after transplant treatment failure
This trial tests tabelecleucel, an immune therapy, for people whose EBV-associated post-transplant lymphoproliferative disease (PTLD) did not respond to rituximab and/or chemotherapy. It may help your immune system better control EBV-driven lymphoma after a transplant.
Duarte, CaliforniaAges Any age - NCT07381738RecruitingPhase 2
Cord blood transplant for Epstein-Barr virus diseases
This trial uses donated umbilical cord blood (a type of stem cell transplant) to treat people with serious illnesses caused by the Epstein-Barr virus. It's an option for those whose disease has not responded to other treatments.
Shanghai, Shanghai MunicipalityAges 14–80 - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Duarte, CaliforniaAges Any age - NCT07488728Recruiting
Letermovir to prevent CMV in children after stem cell transplant
This trial tests if the drug letermovir can prevent a common virus (CMV) in children who have certain blood disorders and are getting a stem cell transplant. It aims to keep you safer during recovery.
Beijing, Beijing MunicipalityAges Up to 18 years - NCT07727083Recruiting
Study of EBV-positive T/NK-cell lymphoma and related diseases
This study collects medical information and blood samples from people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases to better understand how these conditions progress and respond to treatment. It includes a retrospective part (looking back at medical records) and a prospective part (following people forward in time).
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT02579967RecruitingPhase 2
Stem cell transplant for primary immune system disorders
This study tests whether an allogeneic stem cell (bone marrow) transplant can correct an inherited immune problem in people with severe primary immunodeficiencies. It may help reduce life-threatening infections and improve quality of life, depending on your overall health and donor match.
Bethesda, MarylandAges 4–75 - NCT07519356Recruiting
Registry for blood and lymph node disorders
This study collects information from patients with lymphoproliferative disorders—conditions affecting blood and lymph cells—to help doctors better understand these diseases and improve care. Your medical records and information may be used to support research that could benefit future patients.
Pavia, LombardyAges 18 years+ - NCT06271252RecruitingPhase 1
Study of OriCAR-017 for relapsed or refractory multiple myeloma
This trial tests a new type of CAR-T cell therapy called OriCAR-017 for people with multiple myeloma that has come back or not responded to treatment. It is for patients who have already tried several treatments, including ones that target BCMA, and their last treatment stopped working.
Atlanta, GeorgiaAges 18–75 - NCT01555892RecruitingPhase 1
T-cell treatment for EBV-positive lymphomas
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
Houston, TexasAges Any age - NCT04339777RecruitingPhase 2
Bone marrow transplant for inherited immune system disorders
This trial studies how well a donor bone marrow (stem cell) transplant works for people with inherited immune system problems (called immune deficiencies). It’s for patients who haven’t improved with usual treatment or don’t have another good option.
Bethesda, MarylandAges 4–69 - NCT07075185RecruitingPhase 1
Gene therapy study for hard-to-treat multiple myeloma
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
Duarte, CaliforniaAges 18 years+ - NCT07029958RecruitingPhase 4
Transplant protocol for EBV-related T/NK lymphoproliferative disease
This trial tests a stronger transplant conditioning regimen to treat a rare immune disorder caused by the Epstein-Barr virus. It aims to improve outcomes and reduce a complication called graft-versus-host disease, where donor cells attack the patient's body.
BeijingAges birth–18 years - NCT04504526RecruitingEarly Phase 1
New imaging for diagnosing lymphoma
This study tests a new imaging method called CXCR4 PET/CT that may help doctors better see and understand lymphomas (a type of blood cancer). It is for people who are newly diagnosed or suspected of having lymphoma and have already had a standard PET/CT.
Fuzhou, FujianAges 18–80 - NCT00131014Recruiting
Building a family tumor and genetics bank for blood cancers
This study collects and stores tumor/tissue information and family medical history from people with certain blood cancers. It aims to help researchers understand why these illnesses may run in families and use genetic clues for future research.
Boston, MassachusettsAges 18 years+ - NCT05787574RecruitingPhase 2
Reducing inflammation before stem cell transplant in immune disorders
This Phase 2 study tests medicines that calm inflammation before the first stem cell transplant. It aims to make transplant safer and more effective for people with certain inherited immune regulation or inflammatory conditions.
San Francisco, CaliforniaAges Any age - NCT04902807Recruiting
Tool to help decide diagnosis and treatment in immune disorders
This trial tests a tool (a way of collecting health information) to help doctors make better diagnosis, prognosis, and treatment decisions for children with certain immune problems. It also includes healthy children (like relatives) as comparison groups, to see how well the tool works.
ParisAges 1–18 - NCT06741072RecruitingPhase 1
Vaccine to prevent EBV-related cancer in transplant patients
This trial tests a vaccine (OSU-2131) that may help prevent cancers caused by the Epstein-Barr virus in people waiting for an organ transplant. The vaccine is designed to train your immune system to fight the virus.
Columbus, OhioAges 18–65 - NCT00001350Recruiting
Understanding Autoimmune Lymphoproliferative Syndrome
This research study helps doctors understand ALPS, a rare immune disorder that causes swollen lymph nodes and spleen. Participating means providing blood samples and health information so researchers can learn how the condition develops and how to better care for patients.
Bethesda, MarylandAges Up to 99 years - NCT06730126RecruitingPhase 2
Soquelitinib for ALPS-FAS-related swelling and low blood counts
This trial tests an investigational drug called soquelitinib to see if it can shrink enlarged lymph nodes and improve low blood cell counts in people with ALPS-FAS. It may offer a new treatment option for those who have active symptoms.
Bethesda, MarylandAges 16–120 - NCT06716658RecruitingPhase 2
New targeted drug for certain T/NK-cell lymphomas
This trial tests an oral JAK1 inhibitor called golidocitnib for people with T/NK-cell lymphoma that came back after treatment or didn't respond. The drug works by blocking a signal that helps cancer cells grow.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07440290RecruitingPhase 2/Phase 3
Dabrafenib and trametinib for BRAF V600 cancers
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
BelfastAges 1 year+
Hear when a new Lymphoproliferative Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoproliferative disease?
- Yes. Clin2 currently lists 21 recruiting lymphoproliferative disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoproliferative disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoproliferative disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.